Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
11 2019
Historique:
received: 25 03 2019
accepted: 29 06 2019
pubmed: 2 9 2019
medline: 15 7 2020
entrez: 2 9 2019
Statut: ppublish

Résumé

To determine the effects of oxygen therapy in myocardial infarction (MI) patients with and without diabetes. In the Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) trial, 6,629 normoxemic patients with suspected MI were randomized to oxygen at 6 L/min for 6-12 h or ambient air. In this prespecified analysis involving 5,010 patients with confirmed MI, 934 had known diabetes. Oxidative stress may be of particular importance in diabetes, and the primary objective was to study the effect of supplemental oxygen on the composite of all-cause death and rehospitalization with MI or heart failure (HF) at 1 year in patients with and without diabetes. As expected, event rates were significantly higher in patients with diabetes compared with patients without diabetes (main composite end point: hazard ratio [HR] 1.60 [95% CI 1.32-1.93], Despite markedly higher event rates in patients with MI and diabetes, oxygen therapy did not significantly affect 1-year all-cause death, cardiovascular death, or rehospitalization with MI or HF, irrespective of underlying diabetes, in line with the results of the entire study.

Identifiants

pubmed: 31473600
pii: dc19-0590
doi: 10.2337/dc19-0590
doi:

Substances chimiques

Oxygen S88TT14065

Banques de données

ClinicalTrials.gov
['NCT01787110']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2032-2041

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by the American Diabetes Association.

Auteurs

Thomas Nyström (T)

Division of Endocrinology, Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.

Stefan K James (SK)

Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Bertil Lindahl (B)

Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Ollie Östlund (O)

Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

David Erlinge (D)

Cardiology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Johan Herlitz (J)

Department of Health Sciences, University of Borås, Borås, Sweden.

Elmir Omerovic (E)

Department of Molecular and Clinical Medicine and Sahlgrenska University Hospital Department of Cardiology, University of Gothenburg, Gothenburg, Sweden.

Linda Mellbin (L)

Division of Cardiology, Department of Medicine, Solna, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.

Joakim Alfredsson (J)

Department of Medical and Health Sciences and Department of Cardiology, Linköping University, Linköping, Sweden.

Ole Fröbert (O)

Department of Cardiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Tomas Jernberg (T)

Cardiology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH